| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:Camidanlumab
CAS:921618-45-3
Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Camidanlumab (anti-CD25)
CAS:921618-45-3
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14077
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Camidanlumab
CAS:921618-45-3
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Camidanlumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
Camidanlumab manufacturers
- Camidanlumab
-
- $563.00 / 5mg
-
2026-04-09
- CAS:921618-45-3
- Min. Order:
- Purity: 95.00%
- Supply Ability: 10g
|
| | Camidanlumab Basic information |
| Product Name: | Camidanlumab | | Synonyms: | Camidanlumab;Research Grade Camidanlumab(DHB95803);Research Grade Camidanlumab;Camidanlumab (anti-CD25) | | CAS: | 921618-45-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Camidanlumab Structure]() |
| | Camidanlumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Camidanlumab Usage And Synthesis |
| Uses | Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia[1]. | | References | [1] Michael J Flynn, et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Mol Cancer Ther. 2016 Nov;15(11):2709-2721. DOI:10.1158/1535-7163.MCT-16-0233 |
| | Camidanlumab Preparation Products And Raw materials |
|